Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as first line chemotherapy for patients with unresectable advanced esophageal cancer in Japan
The addition of pembrolizumab to chemotherapy was not cost-effective in treating advanced esophageal cancer in Japan.
Authors
- Susumu Kunisawa (ORCID: https://orcid.org/0000-0002-3657-8686)
- Hisashi Itoshima (ORCID: https://orcid.org/0000-0001-9735-4427)
- Michitaka Honda (ORCID: https://orcid.org/0000-0003-3492-9881)
- Kensuke Moriwaki (ORCID: https://orcid.org/0000-0001-5800-597X)
- Yuichi Imanaka (ORCID: https://orcid.org/0000-0003-4613-2159)
- Daisuke Takada (ORCID: https://orcid.org/0000-0002-9601-7629)
- Kiyohide Fushimi (ORCID: https://orcid.org/0000-0002-1894-0290)
- Hirohito Kakinuma
Institutions
- Fukushima Medical University (JP)
- Ritsumeikan University (JP)
- Kyoto University (JP)
- Southern Tohoku General Hospital (JP)
- Doshisha Women's College of Liberal Arts (JP)
Publication Details
- Journal
- Esophagus
- Published
- 2025-07-12
- DOI
- https://doi.org/10.1007/s10388-025-01144-5
- Citations
- 1
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- Japan Society for the Promotion of Science